Overview

PsA Secukinumab XCT Structural Progression Study

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Psoriatic arthritis is related with chronic inflammation and progressive radiographic damages, and it in turn lead to disability and loss in function-ability. Recent advance in treatment pathway through anti IL-17 gives promising clinical improvement. Yet, its effect on radiographic progression remains uncertain. This study aimed to ascertain the effect of secukinumab on structural progression in PsA by evaluation through high resolution peripheral quantative computed tomography (HRpqCT).
Phase:
Phase 4
Details
Lead Sponsor:
Chinese University of Hong Kong
Treatments:
Antibodies, Monoclonal